Routine

Essential (primary) hypertension — outpatient management

Chronic BP control · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Essential hypertension is managed by confirming diagnosis with out-of-office readings, assessing total cardiovascular risk and target-organ damage, then combining lifestyle change with staged pharmacotherapy to a BP target of generally <140/90 (or <130/80 in many).

Red flags

  • BP ≥180/120 with target-organ symptoms (emergency)
  • New visual disturbance or neurological symptoms
  • Signs of acute kidney injury after RAAS blockade
  • Features of phaeochromocytoma or Cushing's
  • Resistant hypertension in a young patient

Assessment

Differential diagnosis

  • Secondary hypertension (renal, endocrine)
  • White-coat hypertension
  • Masked hypertension
  • Medication/substance-induced rise (NSAIDs, decongestants)
  • Obstructive sleep apnoea-related
  • Isolated systolic hypertension of ageing

Investigations

  • Ambulatory or home BP monitoring to confirm diagnosis
  • U&E, eGFR and urine ACR for renal involvement
  • Fasting glucose/HbA1c and lipid profile
  • 12-lead ECG for LVH and ischaemia
  • Fundoscopy for hypertensive retinopathy
  • Calculate 10-year cardiovascular risk

Management

  • Confirm sustained hypertension with ABPM or home readings, not single clinic values
  • Screen for secondary causes if young, resistant, or abrupt/severe
  • Assess target-organ damage and global cardiovascular risk
  • Advise lifestyle measures: salt reduction, weight loss, exercise, alcohol limits, DASH-type diet
  • Start drug therapy based on age/ethnicity: ACEi/ARB for <55 and non-Black, CCB for ≥55 or Black
  • Combine an ACEi/ARB with a CCB or thiazide-like diuretic as step 2
  • Use all three classes together as step 3 before labelling resistant
  • Target <140/90 for most; aim <130/80 if tolerated, diabetes, CKD or high risk
  • Avoid ACEi plus ARB combination due to renal and hyperkalaemia risk
  • Recheck U&E 1-2 weeks after starting/uptitrating ACEi/ARB or diuretic
  • Review adherence and home readings at each visit
  • Escalate to spironolactone-based therapy if BP uncontrolled on three agents

Drugs & doses

Amlodipine 5-10 mg PO OD
Ramipril 2.5-10 mg PO OD (or lisinopril, perindopril)
Losartan 50-100 mg PO OD (or candesartan 8-32 mg OD) if ACEi not tolerated
Indapamide 1.5-2.5 mg PO OD (thiazide-like diuretic)
Spironolactone 25-50 mg PO OD for step 4 if potassium ≤4.5 mmol/L
Doxazosin MR 4-8 mg PO OD or bisoprolol 5-10 mg OD as alternative step 4

Disposition

GP-led chronic management with lifestyle support. Refer to specialist for resistant, secondary, or very young-onset hypertension.

Complications & pitfalls

  • Stroke and cognitive decline
  • Ischaemic heart disease and heart failure
  • Chronic kidney disease progression
  • Hypertensive retinopathy
  • Aortic aneurysm/dissection

Exam pearls

  • Thiazide-like diuretics (indapamide) are preferred over thiazides (bendroflumethiazide) for outcomes
  • A rise in creatinine up to 30% after starting an ACEi/ARB is acceptable
  • Home BP targets run ~5 mmHg lower than clinic targets
  • Single-pill combinations improve adherence and control
  • Check for non-adherence and white-coat effect before escalating in apparent resistance

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.